• Title/Summary/Keyword: 교모세포종

Search Result 27, Processing Time 0.024 seconds

Chemotherapeutic Drug Resistant Cancer Stem-like Cells of Glioma (다형성 교모세포종의 항생제 내성 종양 줄기세포)

  • Kang, Mi-Kyung;Kang, Soo-Kyung
    • Journal of Life Science
    • /
    • v.17 no.8 s.88
    • /
    • pp.1039-1045
    • /
    • 2007
  • Glioblastoma multiforme (GBM) is the most frequently occurring brain cancer. Although the existence of cancer stem cells (CSCs) in GBM has been established, there is little evidence to explain the link between CSCs and chemoresistance. In this study, we investigated that only a few cells of A172 and established GBM2 survived after 1,3-bis(2chloroethyl)-1-nitrosourea (BiCNU) exposures and these sur-vived cells resist the subsequent BiCNU treatment. In addition, these BiCNU-resistant small pop-ulations derived from GBM cells increased the phosphorylations of Erk and Akt and highly expressed CD133 stem cell surface marker. Furthermore, we observed that the BiCNU-resistant cancer cells de-rived from GBM have grown tumors when transplanted into severe combined immuno-deficient (SCID) mouse brain. These results demonstrate that BiCNU-resistant subpopulation cells derived from GBM have cancer stem-like cell properties. Therefore, it may provide provide further evidence that CSCs in GBM have chemotherapeutic drug resistance.

Anticancer activity of chloroform extract of Citrus unshiu Markovich peel against glioblastoma stem cells (교모세포종 암줄기세포에 대한 진피 소수성 추출물의 항암 활성)

  • Kim, Yu Jin;Sim, Ye Eun;Jung, Hye Jin
    • Korean Journal of Food Science and Technology
    • /
    • v.54 no.1
    • /
    • pp.28-34
    • /
    • 2022
  • Glioblastoma is the most common primary malignant brain tumor and has an extremely poor prognosis. Glioblastoma stem cells (GSCs) contribute to tumor initiation, recurrence, and resistance to therapy, and are thus a key therapeutic target. The peel of Citrus unshiu Markovich has been used in traditional medicine in East Asia to treat various diseases. In this study, we investigated the anticancer activity and molecular mechanism of the chloroform extract of this natural product (CECU) in U87MG GSCs. The results show that CECU inhibited the proliferation, tumorsphere formation, and migration of U87MG GSCs by causing cell cycle arrest at the G0/G1 phase and apoptosis. In addition, CECU downregulated key cancer stemness regulators, including CD133, Oct4, Nanog, integrin α6, ALDH1A1, and STAT3 signaling in U87MG GSCs. Furthermore, CECU significantly suppressed in vivo tumor growth of U87MG GSCs in a chorioallantoic membrane model. Therefore, CECU can be utilized as a natural medicine for the prevention and treatment of glioblastoma.

Development of Glioblastoma In Vivo Model for the Research of Brain Cancer Diagnosis and Therapy (뇌암 진단 및 치료 연구를 위한 교모세포종 동물모델 개발)

  • Kang, Seonghee;Kang, Bosun
    • Journal of the Korean Society of Radiology
    • /
    • v.8 no.7
    • /
    • pp.389-395
    • /
    • 2014
  • The research was carried out to develop a animal model of malignant brain tumor for the researches in glioblastoma multiform (GBM) diagnosis and therapy. C6 cells were transplanted into the right striatum of SD rat using stereotactic instrument for the development. The developed animal model was verified by MRI and H&E stain assay of anatomicohistological examination. The MRI observations showed that the tumor developed at the injection site at the 7 days after glioblastoma inoculation. At 14 days post inoculation, the tumor grew to a large volume occupying almost a half of the right cerebral hemisphere. It was confirmed that the expression of excessive mitosis and pleomorphism in anatomicohistological examination. The developed animal model must be necessary and useful tool for the in vivo level research in the development of the new modality for the diagnosis and therapy of brain cancer.

Glioblastoma after Radiotherapy for Pituitary Adenoma (뇌하수체 선종의 방사선치료 후 발생한 교모세포종 - 증례 보고 -)

  • Lee Jong-Young;Park Kyung-Ran;Kim Hun-Joo;Lee Chong-In;Kim Myung-Soon;Jung Soon-Hee
    • Radiation Oncology Journal
    • /
    • v.17 no.4
    • /
    • pp.287-292
    • /
    • 1999
  • A 39-year-old woman developed a glioblastoma about 7 years and 10 months after local radiotherapy (45 Gy) for pituitary adenoma. Clinical and histopathological details are presented, and previously reported cases of radiation-induced glioma are reviewed.

  • PDF

Optimal Radiation Therapy Field for Malignant Astrocytoma and Glioblastoma Multiforme (악성 성상세포종 및 교모세포종의 적정 방사선 조사 영역에 대한 고찰)

  • Cho, Heung-Lae;Choi, Young-Min
    • Radiation Oncology Journal
    • /
    • v.20 no.3
    • /
    • pp.199-205
    • /
    • 2002
  • Purpose : This study was peformed to determine the optimal radiation therapy field for the treatment of malignant astrocytoma and glioblastoma multiforme. Materials and Methods : From Jan. 1994 to Mar. 2000, 21 patients with malignant astrocytoma and glioblastoma multiforme, confirmed as recurrent by follow up MRI after surgery and radiation therapy, were analyzed. The distance from the margin of the primary lesion to the recurrent lesion was measured. The following factors were analyzed to Investigate the influence of these factors to recurrence pattern; tumor size, degree of edema, surgical extent, gamma knife radiosurgery and multiple lesions. Results : Among the 21 patients, 18 $(86\%)$ were recurred within 2 cm from the primary lesion site. 12 within 1 cm, 6 between 1 and 2 cm. The other 3 patients all with multiple lesions, were recurred at 3, 4, 5 cm, from the primary lesion site. The recurrence pattern was not influenced by the factors of tumor size, extent of edema, surgical extent, or gamma knife radiosurgery. However, patients with multiple lesions showed a tendency of recurrence at sites further from the primary lesion. Conclusions : Most $(86\%)$ of the recurrences of malignant astrocytoma and glioblastoma multiforme occurred within 2 cm from the primary lesion site. The width of treatment field does not need to be changed according to tumor size, degree of edema, surgical extent, or gamma knife radiosurgery. However, the treatment field for multiple lesions appears to be wider than that for a single lesion.

Multi-task Deep Neural Network Model for T1CE Image Synthesis and Tumor Region Segmentation in Glioblastoma Patients (교모세포종 환자의 T1CE 영상 생성 및 암 영역분할을 위한 멀티 태스크 심층신경망 모델)

  • Kim, Eunjin;Park, Hyunjin
    • Proceedings of the Korean Institute of Information and Commucation Sciences Conference
    • /
    • 2021.05a
    • /
    • pp.474-476
    • /
    • 2021
  • Glioblastoma is the most common brain malignancies arising from glial cells. Early diagnosis and treatment plan establishment are important, and cancer is diagnosed mainly through T1CE imaging through injection of a contrast agent. However, the risk of injection of gadolinium-based contrast agents is increasing recently. Region segmentation that marks cancer regions in medical images plays a key role in CAD systems, and deep neural network models for synthesizing new images are also being studied. In this study, we propose a model that simultaneously learns the generation of T1CE images and segmentation of cancer regions. The performance of the proposed model is evaluated using similarity measurements including mean square error and peak signal-to-noise ratio, and shows average result values of 21 and 39 dB.

  • PDF

Different Cytokine Dependency of Proneural to Mesenchymal Glioma Stem Cell Transition in Tumor Microenvironments (종양미세환경에서 이질적인 사이토카인에 의한 PN-MES 뇌종양줄기세포 전이 조절)

  • Lee, Seon Yong;Kim, Hyunggee
    • Journal of Life Science
    • /
    • v.29 no.5
    • /
    • pp.530-536
    • /
    • 2019
  • Glioblastoma (GBM) is the most incurable brain cancer derived from the transformed glial cells. Standard anti-GBM treatment, including surgery and chemoradiotherapy, does not ensure good prognosis for the patients with GBM, because successful therapy is often impeded by presence of glioma stem cells (GSCs). GSCs, which is generally divided into proneural (PN) and mesenchymal (MES) subtype, are understood as subpopulation of cancer cells responsible for GBM initiation, progression and recurrence after standard treatments. In the present study, we demonstrate that PN subtype GSCs differentially transit to MES subtype GSCs by specific cytokines. The expression of CD44, a marker of MES subtype GSCs, was observed when GSC11 PN subtype GSCs were exposed to tumor necrosis factor alpha ($TNF-{\alpha}$) cytokine and GSC23 PN subtype GSCs were treated to transforming growth factor beta 1 ($TGF-{\beta}1$) cytokine. Ivy glioblastoma atlas project (Ivy GAP) bioinformatics database showed that $TNF-{\alpha}$ and $TGF-{\beta}1$ were highly expressed in necrotic region and perivascular region, respectively. In addition, $TNF-{\alpha}$ signaling was relatively upregulated in necrotic region, while $TGF-{\beta}$ signaling was increased in perivascular region. Taken together, our observations suggest that MES subtype GSCs can be derived from various PN subtype GSCs by multimodal cytokine stimuli provided by neighboring tumor microenvironment.

Anticancer Effect of Novel Peptide from Abalone (Haliotis discus hannai) based on Next Generation Sequencing Data (차세대염기서열분석 데이터 기반으로 선별한 전복(Haliotis discus hannai) 유래 신규 펩타이드의 항암 효과)

  • Moon, Hyunhye;Hwang-bo, Jeon;Veerappan, Karpagam;Natarajan, Sathishkumar;Chung, Hoyong;Park, Junhyung
    • Journal of Marine Life Science
    • /
    • v.7 no.1
    • /
    • pp.15-20
    • /
    • 2022
  • Glioblastoma is one of the highly aggressive central nervous system tumors and it is difficult to treat owing its anatomical location. Peptides are novel class of drugs which has the potential to cross the blood brain barrier and exerts its anti-tumor activity. Here, we discovered a novel peptide from abalone (Haliotis discus hannai) next generation sequencing (NGS) data and tested its anticancer effect on glioblastoma cell line SNU-489. The anticancer activity was measured using a cytotoxicity assay in a time and dose-dependent manner. A concentration and time dependent increase in the cytotoxicity was seen in cells treated with the novel peptide. The highest cytotoxicity rate of about 67% was observed in SNU-489 cells treated with 200 µM peptide for 48 hrs. However, the cytotoxic effect was not or less observed in a normal skin cell line HaCaT at similar concentration, thus, evident of peptide's cell specific anticancer activity. In addition, the gene expression level of necroptosis-related genes was analyzed by qRT-PCR to elucidate the anticancer mechanism of the novel peptide. RIPK3 expression was significantly increased by 9.6-fold in 200 µM of novel peptide treatment group, and MLKL expression level was significantly elevated by 2-fold in 100 µM treated group compared to the control group. Therefore, this study confirmed that the novel abalone-derived peptide has anticancer potency, and it causes cancer cell death through the necroptosis mechanism. Collectively, these results suggest that the novel peptide could be candidate anticancer agent for the treatment of glioblastoma in the future.

Caring for Dying Patient with Glioblastoma Multiforme: A Narrative Analysis of the Caring Experience of Family Caregiver (가족 돌봄제공자의 말기 교모세포종 환자 돌봄경험-갈등과정에 대한 내러티브 분석)

  • Kim, Myung-Ah;Ryu, Eun-Jung;Hong, Yeon-Pyo
    • Asian Oncology Nursing
    • /
    • v.12 no.2
    • /
    • pp.186-193
    • /
    • 2012
  • Purpose: The purpose of this narrative study was to understand how family caregivers interpreted themselves life during caring for dying patients with gliobalstoma, and how they integrated these experiences into their personal biographies. Methods: Three family caregivers were recruited for the study. Data were collected through a series of audio-taped unstructured interviews and conversations with participants. The interviews and observation were conducted between October and November, 2011. Data were analyzed using psychosocial analytical methods that combined case based, in-depth staged analysis of narratives. Results: The life experiences of the family caregivers with a dying family member were summarized as, in their own voices, 'the repetition of gliobalstoma,' 'a smart patient,' 'being obsessed with rehabilitation treatment,' 'the frustration from nothing but just looking at the suffering of the patient,' and 'a stubborn son'. Conclusion: Caregiving was characterised by various roles and life changes from the moment of diagnosis. Family caregivers of brain tumor reported experiences similar to those described by caregivers of people with other cancers. What differed for this group was the rapidity of change and the need for immediate information and support to assist with caring for a person with high-grade glioma.

Case Report on Long Term Survival of Glioblastoma Patient Treated with Integrative Medicine (한양방결합치료로 장기간 생존하고 있는 교모세포종 증례 보고)

  • Yang, Juno;Yun, Youngju;Hong, Jinwoo;Han, Changwoo;Kwon, Jungnam;Lee, In;Park, Seongha;Kim, Soyeon;Choi, Junyong;Lee, Hyeyoon
    • The Journal of Korean Medicine
    • /
    • v.39 no.1
    • /
    • pp.75-85
    • /
    • 2018
  • Objectives: This is a long-term survival case report about glioblastoma treated with western medicine and traditional Korean medicine. 28 year-old man diagnosed glioblastoma in 2003 went through 2 year's chemotherapy first. After emergency brain surgery he took acupuncture and Korean herbal medication including Dohongsamul-tang and Boan-Manyeongdan in addition to conventional radiotherapy and chemotherapy for 3 years. Since May 2008, he was exclusively treated with traditional Korean medicine except taking antiplatelets only for 9 years. Though he has sequelae of tumor necrosis such as facial palsy and hemiparesis, he has survived without recurrence more than 14 years. We suggest that integrative approach including traditional Korean medicine can be a meaningful treatment option for malignant brain tumor. Further studies with more cases should be performed to establish proper treatment protocol of integrative medicine for brain tumor.